• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

辉瑞/生物科技公司的 COVID-19 疫苗皮下接种可使年轻人产生血清转化。

Sub-cutaneous Pfizer/BioNTech COVID-19 vaccine administration results in seroconversion among young adults.

机构信息

Israeli Defense Forces Medical Corps, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Israeli Defense Forces Medical Corps, Israel.

出版信息

Vaccine. 2021 Oct 8;39(42):6210-6212. doi: 10.1016/j.vaccine.2021.07.096. Epub 2021 Aug 5.

DOI:10.1016/j.vaccine.2021.07.096
PMID:34531083
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8339541/
Abstract

Route of vaccine administration plays a role in extent and quality of immunogenicity. 790 military personnel accidentally received the first of two doses of Pfizer/BioNTech mRNA anti Covid-19 vaccine using a needle intended for subcutaneous administration. A serological blood test (on day 21, prior to the second intramuscular dose) was performed, analyzing whether immunological response was elicited. 98.2% demonstrated seroconversion. IgG titers were negatively correlated with age and did not correlate with BMI. Our results could help reassure providers confronted with a similar mistake and may even imply a possibly new and effective administration route.

摘要

疫苗接种途径在免疫原性的程度和质量方面发挥作用。790 名军事人员在无意中使用皮下注射用针头接种了两剂辉瑞/生物科技 mRNA 抗新冠病毒疫苗的第一剂。在(第二次肌肉注射前的第 21 天)进行了血清学血液检测,以分析是否引发了免疫反应。98.2%的人出现了血清转化。IgG 滴度与年龄呈负相关,与 BMI 无关。我们的结果可以帮助安抚遇到类似错误的医务人员,甚至可能暗示一种新的、有效的接种途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bb9/8339541/0350e520ddb2/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bb9/8339541/0350e520ddb2/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bb9/8339541/0350e520ddb2/gr1_lrg.jpg

相似文献

1
Sub-cutaneous Pfizer/BioNTech COVID-19 vaccine administration results in seroconversion among young adults.辉瑞/生物科技公司的 COVID-19 疫苗皮下接种可使年轻人产生血清转化。
Vaccine. 2021 Oct 8;39(42):6210-6212. doi: 10.1016/j.vaccine.2021.07.096. Epub 2021 Aug 5.
2
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.立陶宛血液系统恶性肿瘤患者的 BNT162b2 COVID-19 mRNA 疫苗免疫原性和早期临床结局:一项全国前瞻性队列研究。
Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.
3
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.COVID-19 疫苗:辉瑞/生物科技和 Moderna 疫苗的生物学、药理学特征和不良反应比较。
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.
4
Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.评估接受血液透析患者对 BNT162b2 疫苗的 SARS-CoV-2 抗体反应。
JAMA Netw Open. 2021 Sep 1;4(9):e2123622. doi: 10.1001/jamanetworkopen.2021.23622.
5
[Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].[卡斯蒂利亚-莱昂社会医疗中心工作人员接种辉瑞/生物科技公司的BNT162b2 mRNA疫苗后对严重急性呼吸综合征冠状病毒2的体液免疫。]
Rev Esp Salud Publica. 2021 Oct 25;95:e202110141.
6
BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.BNT162b2 新冠病毒疫苗与体液免疫应答及动力学的相关性:医护人员前瞻性、单中心、纵向队列研究。
Lancet Respir Med. 2021 Sep;9(9):999-1009. doi: 10.1016/S2213-2600(21)00220-4. Epub 2021 Jul 2.
7
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.2021年3月至8月美国Moderna、辉瑞-生物科技公司和杨森(强生)疫苗在预防无免疫功能低下状况成年人新冠病毒肺炎住院方面的比较效果
MMWR Morb Mortal Wkly Rep. 2021 Sep 24;70(38):1337-1343. doi: 10.15585/mmwr.mm7038e1.
8
Higher antibody responses after mRNA-based vaccine compared to inactivated vaccine against SARS-CoV-2 in Behcet's syndrome.与针对 SARS-CoV-2 的灭活疫苗相比,在 Behcet 综合征患者中,基于 mRNA 的疫苗产生的抗体反应更高。
Rheumatol Int. 2022 Oct;42(10):1741-1750. doi: 10.1007/s00296-022-05164-7. Epub 2022 Jul 2.
9
The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.mRNA-1273 新冠病毒疫苗在血液透析患者中的安全性和免疫原性。
Front Immunol. 2021 Jun 16;12:704773. doi: 10.3389/fimmu.2021.704773. eCollection 2021.
10
Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.智利科兴和国药疫苗接种后动态 IgG 血清阳性率:哨点监测研究。
Lancet Infect Dis. 2022 Jan;22(1):56-63. doi: 10.1016/S1473-3099(21)00479-5. Epub 2021 Sep 9.

引用本文的文献

1
DLin-MC3-Containing mRNA Lipid Nanoparticles Induce an Antibody Th2-Biased Immune Response Polarization in a Delivery Route-Dependent Manner in Mice.含DLin-MC3的信使核糖核酸脂质纳米颗粒在小鼠体内以依赖递送途径的方式诱导抗体Th2偏向性免疫反应极化。
Pharmaceutics. 2023 Mar 21;15(3):1009. doi: 10.3390/pharmaceutics15031009.
2
Qualitative Conceptual Content Analysis of COVID-19 Vaccine Administration Error Inquiries.新型冠状病毒肺炎疫苗接种错误查询的定性概念内容分析
Vaccines (Basel). 2023 Jan 24;11(2):254. doi: 10.3390/vaccines11020254.
3
Principles for optimization and validation of mRNA lipid nanoparticle vaccines against COVID-19 using 3D bioprinting.

本文引用的文献

1
Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021.2020 年 12 月至 2021 年 1 月,以色列医护人员的真实世界数据显示,年龄、种族、性别和既往感染状况对接受一剂 BNT162b2 mRNA COVID-19 疫苗后的免疫原性有影响。
Euro Surveill. 2021 Feb;26(6). doi: 10.2807/1560-7917.ES.2021.26.6.2100096.
2
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
3
使用3D生物打印优化和验证针对COVID-19的mRNA脂质纳米颗粒疫苗的原则
Nano Today. 2022 Apr;43:101403. doi: 10.1016/j.nantod.2022.101403. Epub 2022 Jan 21.
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.
一项在成人中开展的 COVID-19 RNA 疫苗 BNT162b1 的 I/II 期研究。
Nature. 2020 Oct;586(7830):589-593. doi: 10.1038/s41586-020-2639-4. Epub 2020 Aug 12.
4
Evaluation of solid lipid nanoparticles as carriers for delivery of hepatitis B surface antigen for vaccination using subcutaneous route.评价固体脂质纳米粒作为乙型肝炎表面抗原经皮给药疫苗载体的研究
J Pharm Pharm Sci. 2010;13(4):495-509. doi: 10.18433/j3xk53.
5
Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems.给药途径影响免疫应答的质量:颗粒性抗原递呈系统的横断面评价。
J Control Release. 2010 Nov 1;147(3):342-9. doi: 10.1016/j.jconrel.2010.08.012. Epub 2010 Aug 18.
6
What role does the route of immunization play in the generation of protective immunity against mucosal pathogens?免疫途径在针对黏膜病原体产生保护性免疫中起什么作用?
J Immunol. 2009 Dec 1;183(11):6883-92. doi: 10.4049/jimmunol.0901466.
7
A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice.皮下注射紫外线灭活的严重急性呼吸综合征冠状病毒疫苗可在小鼠体内引发全身性体液免疫。
Int Immunol. 2004 Oct;16(10):1423-30. doi: 10.1093/intimm/dxh143. Epub 2004 Aug 16.